116 related articles for article (PubMed ID: 36542180)
1. Mathematical Model of Triple-Negative Breast Cancer in Response to Combination Chemotherapies.
Davenport AA; Lu Y; Gallegos CA; Massicano AVF; Heinzman KA; Song PN; Sorace AG; Cogan NG
Bull Math Biol; 2022 Dec; 85(1):7. PubMed ID: 36542180
[TBL] [Abstract][Full Text] [Related]
2. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
3. Synergistic Anti-Tumor Effect of Toosendanin and Paclitaxel on Triple-Negative Breast Cancer via Regulating ADORA2A-EMT Related Signaling.
Zhang J; Xu HX; Wu YL; Cho WCS; Xian YF; Lin ZX
Adv Biol (Weinh); 2023 Aug; 7(8):e2300062. PubMed ID: 37401656
[TBL] [Abstract][Full Text] [Related]
4. Zhuidu Formula suppresses the migratory and invasive properties of triple-negative breast cancer cells via dual signaling pathways of RhoA/ROCK and CDC42/MRCK.
Wu Q; Ma X; Jin Z; Ni R; Pan Y; Yang G
J Ethnopharmacol; 2023 Oct; 315():116644. PubMed ID: 37196814
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of p300 in paclitaxel-resistant TNBC: implications for cell proliferation via the PCK1/AMPK axis.
Zhao PW; Cui JX; Wang XM
Pharmacogenomics J; 2024 Feb; 24(2):5. PubMed ID: 38378770
[TBL] [Abstract][Full Text] [Related]
6. [18F]FDG and [18F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer.
Raccagni I; Belloli S; Valtorta S; Stefano A; Presotto L; Pascali C; Bogni A; Tortoreto M; Zaffaroni N; Daidone MG; Russo G; Bombardieri E; Moresco RM
PLoS One; 2018; 13(5):e0197754. PubMed ID: 29791503
[TBL] [Abstract][Full Text] [Related]
7. Low Dose of Paclitaxel Combined with XAV939 Attenuates Metastasis, Angiogenesis and Growth in Breast Cancer by Suppressing Wnt Signaling.
Shetti D; Zhang B; Fan C; Mo C; Lee BH; Wei K
Cells; 2019 Aug; 8(8):. PubMed ID: 31416135
[TBL] [Abstract][Full Text] [Related]
8.
Ma G; Liu C; Lian W; Zhang Y; Yuan H; Zhang Y; Song S; Yang Z
Ann Nucl Med; 2021 May; 35(5):600-607. PubMed ID: 33689138
[TBL] [Abstract][Full Text] [Related]
9. Noninvasive Classification of Human Triple Negative Breast Cancer by PET Imaging with GRP78-Targeted Molecular Probe [
Zhao H; Meng H; Wen J; Wang C; Liu J; Huang G
Mol Imaging Biol; 2020 Jun; 22(3):772-779. PubMed ID: 31452065
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
[TBL] [Abstract][Full Text] [Related]
11. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
Speyer CL; Bukhsh MA; Jafry WS; Sexton RE; Bandyopadhyay S; Gorski DH
Breast Cancer Res Treat; 2017 Nov; 166(2):407-419. PubMed ID: 28780701
[TBL] [Abstract][Full Text] [Related]
12. RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage.
Haynes BM; Cunningham K; Shekhar MPV
BMC Cancer; 2022 Oct; 22(1):1073. PubMed ID: 36258187
[TBL] [Abstract][Full Text] [Related]
13. Synergistic enhancement of apoptosis by coralyne and paclitaxel in combination on MDA-MB-231 a triple-negative breast cancer cell line.
Kumari S; Mohan MG; Shailender G; Badana AK; Malla RR
J Cell Biochem; 2019 Oct; 120(10):18104-18116. PubMed ID: 31172606
[TBL] [Abstract][Full Text] [Related]
14. A Novel Paclitaxel Derivative for Triple-Negative Breast Cancer Chemotherapy.
Liu Y; Hong G; Mao L; Su Z; Liu T; Liu H
Molecules; 2023 Apr; 28(9):. PubMed ID: 37175072
[TBL] [Abstract][Full Text] [Related]
15. Synergistic effect of human uterine cervical mesenchymal stem cell secretome and paclitaxel on triple negative breast cancer.
Eiro N; Fraile M; Escudero-Cernuda S; Sendon-Lago J; Gonzalez LO; Fernandez-Sánchez ML; Vizoso FJ
Stem Cell Res Ther; 2024 Apr; 15(1):121. PubMed ID: 38664697
[TBL] [Abstract][Full Text] [Related]
16. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.
Martin JL; Julovi SM; Lin MZ; de Silva HC; Boyle FM; Baxter RC
Breast Cancer Res; 2017 Aug; 19(1):90. PubMed ID: 28778177
[TBL] [Abstract][Full Text] [Related]
18. Cellular uptake mechanism and comparative evaluation of antineoplastic effects of paclitaxel-cholesterol lipid emulsion on triple-negative and non-triple-negative breast cancer cell lines.
Ye J; Xia X; Dong W; Hao H; Meng L; Yang Y; Wang R; Lyu Y; Liu Y
Int J Nanomedicine; 2016; 11():4125-40. PubMed ID: 27601899
[TBL] [Abstract][Full Text] [Related]
19. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
20. [Effect of miR-342-3p on chemotherapy sensitivity in triple-negative breast cancer].
Ma T; Zhang J; Wu J; Tang J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 May; 39(5):488-95. PubMed ID: 24921394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]